Superior specificity of anti-citrullinated peptide antibodies in patients with chronic lymphocytic leukaemia and arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 6, 2010, Pages 888-891

  Brickmann, K ^a   Brezinschek, R I ^a   Yazdani Biuki, B ^a   Graninger, W B ^a   Brezinschek, H P ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Anti cyclic citrullinated peptide antibodies; B cell chronic lymphocytic leukaemia; Paraneoplastic arthritis; RA diagnosis; Rheumatoid factor

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FLUDARABINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; ANTIIDIOTYPIC ANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; B CELL LEUKEMIA; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 79952669954     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. BORCHE L, LIM A, BINET JL, DIGHIERO G: Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990; 76: 562-9.
2. FORSLIND K, AHLMEN M, EBERHARDT K, HAFSTROM I, SVENSSON B: Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090-5.
3. MORITA Y, MURO Y, SUGIURA K, TOMITA Y: Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol 2008; 26: 542-5.
4. GOEB V, SALLE V, DUHAUT P et al.: Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome. Clin Exp Immunol 2007; 148: 281-7.
5. INANC N, DALKILIC E, KAMALI S et al.: Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007; 26: 17-23.
6. HOFFMAN IE, PEENE I, CEBECAUER L et al.: Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 330-2.
7. LIU FC, CHAO YC, HOU TY et al.; Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia. Clin Rheumatol 2008; 27: 463-7.
8. KOGA T, MIGITA K, MIYASHITA T et al.: Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol 2008; 26: 121-4.
9. Arnett FC, Edworthy SM, Bloch DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
10. HERNANDEZ JM, MECUCCI C, CRIEL A et al.: Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia 1995; 9: 2140-6.
11. CALIGARIS-CAPPIO F, HAMBLIN TJ: B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999; 17: 399-408.
12. DUEK A, SHVIDEL L, BRAESTER A, BERREBI A: Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J 2006; 8: 828-31.
13. Barcellini W, Capalbo S, AGOSTINELLI RM et at: Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006; 91: 1689-92. (Pubitemid 46032967)
14. VALERIANO J: Malignancy and rheumatic disease. Cancer Control 1997; 4: 236-44.
15. TAYLOR HG, NIXON N, SHEERAN TP, DAWES PT: Rheumatoid arthritis and chronic lymphatic leukaemia. Clin Exp Rheumatol 1989; 7: 529-32.
16. BAECKLUND E, SUNDSTROM C, EKBOM A et al.: Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003; 48: 1543-50.
17. VOULGARI PV, VARTHOLOMATOS G, KAIAFAS P, BOURANTAS KL, DROSOS AA: Rheumatoid arthritis and B-cell chronic lymphocytic leukemia. Clin Exp Rheumatol 2002; 20: 63-5.
18. Birlik M, Akar S, Onen F et al.: Articular, B-cell, non-Hodgkin's lymphoma mimicking rheumatoid arthritis: synovial involvement in a small hand joint. Rheumatol Int 2004; 24: 169-72. (Pubitemid 38797632)
19. ONAL IK, OZCAKAR L, DIZDAR O, BUYUKASIK Y, DUNDAR S: Seropositive arthritis in chronic lymphocytic leukemia: a remark on B cell-mediated autoimmunity. Rheumatol Int 2005; 25: 569-70.
20. RANTAPÄÄ-DAHLQVIST S, DE JONG BAW, BERGLIN E et al:. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-49.
21. VALLBRACHT I, RIEBER J, OPPERMANN M et al.: Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1079-84.